Compare IOVA & PCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IOVA | PCT |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Environmental Services |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2008 | 2020 |
| Metric | IOVA | PCT |
|---|---|---|
| Price | $7.03 | $6.88 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 3 |
| Target Price | $9.00 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 17.2M | 4.1M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 14.84 | ★ 30.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,355,000.00 |
| Revenue This Year | $47.74 | $380.44 |
| Revenue Next Year | $40.31 | $203.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.76 | $4.93 |
| 52 Week High | $7.25 | $15.49 |
| Indicator | IOVA | PCT |
|---|---|---|
| Relative Strength Index (RSI) | 71.00 | 47.72 |
| Support Level | $3.57 | $5.02 |
| Resistance Level | N/A | $9.56 |
| Average True Range (ATR) | 0.47 | 0.50 |
| MACD | 0.17 | 0.11 |
| Stochastic Oscillator | 89.70 | 48.23 |
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.